目的 :探讨一种新型重组融合基因抗体导向溶栓剂SZ5 1Hu scuPA的体外溶栓效力。方法 :通过转瓶扩大生产获得的大量基因重组融合蛋白SZ5 1Hu scuPA ,通过抗体竞争结合实验确定融合蛋白的抗体亲和力 ;进而与尿激酶进行不同浓度血小板血浆凝块体外溶栓比较。结果 :该融合蛋白体外纤溶活性为 390 0 0U mg ;其抗体亲和力是鼠源性单抗的 6 7% ;体外溶栓效力较uPA提高 4.1～ 8.4倍。结论 :体外溶栓结果证明 ,融合蛋白SZ5 1Hu scuPA既兼有与人活化血小板结合特性又有纤溶酶原激活剂特性的双功能分子 ,是一种新型的抗体导向溶栓剂 Objective: To investigate the in vitro thrombolytic efficacy of a novel recombinant fusion gene antibody-directed thrombolytic agent SZ5 1Hu scuPA. Methods: A large amount of gene recombinant fusion protein SZ5 1Hu scuPA was amplified by spinner flask, and the antibody affinity of the fusion protein was determined by competitive antibody binding assay. Furthermore, the thrombolytic activity of urokinase in vitro was compared with that of urokinase in vitro. RESULTS: The in vitro fibrinolytic activity of the fusion protein was 390 0U mg. The antibody affinity of the fusion protein was 67% of that of murine monoclonal antibody. The in vitro thrombolysis efficacy was 4.1 ~ 8.4 times higher than that of uPA. Conclusion: The results of in vitro thrombolysis proved that the fusion protein SZ5 1Hu scuPA is a new type of antibody-guided thrombolytic agent, which is a bifunctional molecule that combines both human activated platelets and plasminogen activator